Anti-fibrotic effects of Orostachys japonicus A. Berger (Crassulaceae) on hepatic stellate cells and thioacetamide-induced fibrosis in rats.
10.4162/nrp.2017.11.6.470
- Author:
Sushruta KOPPULA
1
;
Mun Jeong YUM
;
Jin Seoub KIM
;
Gwang Mo SHIN
;
Yun Jin CHAE
;
Tony YOON
;
Chi Su CHUN
;
Jae Dong LEE
;
MinDong SONG
Author Information
1. Department of Biotechnology, College of Biomedical and Health Sciences, Konkuk University, 268 Chungwon-daero, Chungju-si, Chungbuk 27478, Korea. minds@kku.ac.kr
- Publication Type:Original Article
- Keywords:
Liver;
glutathione;
hydroxyproline;
apoptosis;
silymarin
- MeSH:
Animals;
Apoptosis;
Asian Continental Ancestry Group;
Biomarkers;
Cell Cycle;
Cell Survival;
Fibrosis*;
Flow Cytometry;
Gene Expression;
Glutathione;
Hepatic Stellate Cells*;
Humans;
Hydroxyproline;
In Vitro Techniques;
Korea;
Liver;
Liver Cirrhosis;
Models, Animal;
Rats*;
Rats, Sprague-Dawley;
Silymarin;
Spectrophotometry;
Thioacetamide
- From:Nutrition Research and Practice
2017;11(6):470-478
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/OBJECTIVE: Orostachys japonicus A. Berger (Crassulaceae) has been used in traditional herbal medicines in Korea and other Asian countries to treat various diseases, including liver disorders. In the present study, the anti-fibrotic effects of O. japonicus extract (OJE) in cellular and experimental hepatofibrotic rat models were investigated. MATERIALS/METHODS: An in vitro hepatic stellate cells (HSCs) system was used to estimate cell viability, cell cycle and apoptosis by MTT assay, flow cytometry, and Annexin V-FITC/PI staining techniques, respectively. In addition, thioacetamide (TAA)-induced liver fibrosis was established in Sprague Dawley rats. Briefly, animals were divided into five groups (n = 8): Control, TAA, OJE 10 (TAA with OJE 10 mg/kg), OJE 100 (TAA with OJE 100 mg/kg) and silymarin (TAA with Silymarin 50 mg/kg). Fibrosis was induced by treatment with TAA (200 mg/kg, i.p.) twice per week for 13 weeks, while OJE and silymarin were administered orally two times per week from week 7 to 13. The fibrotic related gene expression serum biomarkers glutathione and hydroxyproline were estimated by RT-PCR and spectrophotometry, respectively, using commercial kits. RESULTS: OJE (0.5 and 0.1 mg/mL) and silymarin (0.05 mg/mL) treatment significantly (P < 0.01 and P < 0.001) induced apoptosis (16.95% and 27.48% for OJE and 25.87% for silymarin, respectively) in HSC-T6 cells when compared with the control group (9.09%). Further, rat primary HSCs showed changes in morphology in response to OJE 0.1 mg/mL treatment. In in vivo studies, OJE (10 and 100 mg/kg) treatment significantly ameliorated TAA-induced alterations in levels of serum biomarkers, fibrotic related gene expression, glutathione, and hydroxyproline (P < 0.05-P < 0.001) and rescued the histopathological changes. CONCLUSIONS: OJE can be developed as a potential agent for the treatment of hepatofibrosis.
